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Background/aim: Neurotrophins are one of the most important molecule groups affecting cerebral neuroplasticity. The amount of
evidence about the role of changes in neuroplasticity in the pathophysiology of bipolar disease is growing.
Materials and methods: We measured serum levels of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF),
neurotrophin-3 (NT-3), glial cell-line derived neurotrophic factor (GDNF), vascular endothelial growth factor (VEGF), insulin-like
growth factor-1 (IGF-1), fibroblast growth factor (FGF)-2, neuritin 1 (Nrn 1) in bipolar 1 manic episode patients (n = 45) and healthy
control group.
Results: When controlled for age, BMI and cortisol, it was found that the serum levels of BDNF, NGF, NT-3, VEGF and FGF-2 of
bipolar manic episode patients were not statistically different compared to those of the control group. GDNF level and Nrn 1 levels
were significantly lower (P = 0.003 and P = 0.025 respectively) while IGF-1 levels were significantly higher than the control group (P
= 0.0001). ROC analysis was performed and the area under the the curve was calculated as 0.737, 0.766 for GDNF, IGF-1 respectively.
Conclusion: The changes in the levels of GDNF, IGF-1 and Nrn 1 might be involved in pathopysiology of bipolar disorder, and GDNF,
IGF-1 may be considered as state markers in bipolar manic episode.
Keywords: Bipolar disorder, neurotrophic factors, IGF-1, GDNF, neuritin 1

1. Introduction
Bipolar disorder is a multifactorial disease in which
inflammation, oxidative stress and neurotropic factors
play a role [1]. All these factors affect neuroplasticity and
the impairment in neuroplasticity has a central role in the
pathophysiology and treatment of bipolar disorder [2].
Neurotrophins are the principal regulators affecting
neuroplasticity and these proteins are crucial in neural
survival, growth and functioning [3]. BDNF, NGF
and NT-3, the neurotropic factors, are synthesized
as proneurotrophin and are converted into mature
neurotrophines by cleavage. These proneurotrophines
bind to Trk and P75NTR receptors and modify neural
survival, growth and plasticity by activating signal
pathways including Ras/ERK, PI3k/AKT and PLCϒ [4].
The homeostasis disturbances in these neurotrophic
factors may contribute to cerebral atrophy and progressive
cognitive disorder observed in bipolar disorder [5,6,7].
GDNF is a member of transforming growth factor β
super family and is synthesized in many parts of the brain

[8]. It is not only related with the dopaminergic neurons
in mesencephalon [9] but also with the growth of central
and peripheral nervous system and protection of plasticity
[10]. GDNF may have this effect by reducing the oxidative
stress [11]. However, there are a limited number of studies
on the relationship between bipolar disorder and the level
of GDNF and, there is no consensus on the results of these
studies [12].
VEGF, IGF-1 and FGF-2 are called angioneurins. They
are growth factors with both neurotropic and neurovascular
effects [13]. VEGF increases neuron proliferation in
hippocampus [14] and, genetic variations of VEGF are
associated with the morphology of hippocampus [15].
Increased VEGF level may be an indicator of compensatory
response to the restoration of neurogenesis in bipolar
patients at manic episode [16]. IGF-1 is a growth factor
most of which is synthesized out of the central nervous
system, namely in liver, and affects synaptic plasticity
by passing the blood-brain barrier. It achieves this effect
via glutamatergic synaps [17]. It was observed that IGF
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Binding Protein-2 (IGFBP-2) level decreased in the brain
in bipolar disorder [18]. However, increased peripheral
IGF-1 levels in bipolar disorder may be related with the
absence of negative feedback resulting from the reduced
central effect of IGF-1 [19]. FGF-2 is produced in many
parts of the brain and is important in neural survival and
growth [20]. Reduced expression of this neurotropic factor
and its receptors may be related with mental diseases [21].
There is only one study investigating the relationship
between bipolar disease and FGF-2 and it suggests that
FGF-2 levels increase in manic episode [13]. Yet, further
studies on the subject are required.
Neuritin is a protein which supports neuritogenesis,
particularly in hippocampus and cortical cells, by affecting
glycosylphosphatidylinositol [22]. Nrn 1 is aneuritin
homolog and regulates dendritic and axonal branching
[23]. It also increases synaptic maturation and neural
migration [24]. It is proposed that reduced neuronal
dendritic branching, hippocampus plasticity and limbic
structure are related with the mood disorders. Therefore,
changes in the expression of neuritin may be related with
mood disorders. It was reported that application of chronic
stress reduced the expression of neuritin in hippocampus
and that the use of antidepressants reversed this process
[25]. In another study conducted on schizophrenia
patients, it was proposed that impairment in general
intelligence was related with polymorphism in Nrn 1 gene
[26]. In the light of this information, changes in the level
of Nrn 1 may play a role in the etiopathogenesis of bipolar
disorder. We have not found any study in literature on the
relationship between bipolar disorder and neuritin 1.
It is proposed that abnormal cortisol metabolism
is related with the disfunctioning of hypothalamohypophyseal axis in bipolar patients [27]. Studies
conducted before 2014 were reviewed in a recent metaanalysis and it was found that the cortisol level increased
slightly in bipolar patients during depressive and euthymic
episodes [28]. Increased cortisol levels may play a role
by decreasing the levels of neurotrophic factors [29].
In addition, another factor which may have an effect on
neurotropic factor is obesity. [30]. Neurotropic factors
seem to be effective in body weight control and it argued
that there is a significant reduction of these factors in
obese individuals [31]. Another factor is ageing and
metabolic changes in brain during the ageing process
may be accompanied by a decrease in the expression of
neurotropoic factors [32]. Thus, studies on this subject
need to consider the relationship between the age, BMI,
cortisol levels, and neurotrophic levels of the patients.
In the light of the abovementioned information, there
may be a relation between bipolar disorder and neurotropic
factors (BDNF, NGF, NT-3, GDNF, VEGF, IGF-1, FGF-2
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and Nrn 1). However, the research on this subject is limited
and is far from revealing the relation between neurotropic
factors and bipolar disorder. We aimed to reveal whether
there was a change in neurotropic factors during the manic
episode of type 1 bipolar patients by keeping the effects
of potential confounding factors such as age, BMI and
cortisol level. We also analyzed the relationship between
these parameters and the sociademographic and clinical
features of the disorder.
2. Material and methods
2.1. Subjects
This study was conducted on bipolar disorder Type 1
manic episode patients of 18 to 65 years old who applied
to Ondokuz Mayıs University, Faculty of Medicine,
Department of Psychiatry (n = 45) and a control
group (n = 45). All subjects were evaluated by at least 2
psychiatrists. Diagnosis of bipolar disorder manic episode
was made using DSM-IV (The diagnostic and statistical
manual of mental disorders, 4th edition). The mania
severity was measured using YMRS (young mania rating
scale) [33]. Comorbidity was evaluated for all subjects
using SCID-I (structured clinical interview for DSM-IV
Axis I disorders) [34] and SCID-II (structured clinical
interview for DSM-III-R personality disorder) [35].
Subjects with a potential of psychiatric comorbidity were
excluded from the study. The control group matched with
patient groups regarding age and sex and had never had
a psychiatric disease. All subjects had a body index of ≤
25 kg/m2 and were nonsmokers. In addition, none of the
subjects had drug addiction, pregnancy, breastfeeding or
chronic disease (infection, inflammatory disease, diabetes,
hypertension, cancer and etc.). This study was approved by
Ondokuz Mayıs University, Ethical Committee of Clinical
Research (No: 2014/755 Issue B.30.2.ODM.0.20.08/162).
All procedures were organized in accordance with World
Health Organization’s Helsinki Declaration. All subjects
were informed and written consent was received.
2.2. Collection of blood
5 mL of blood was taken from each participant into the
biochemistry tubes after 12 h fasting at 8:00–10:00 AM.
The blood collected was centrifugated (Jouan C4i Cat no:
11177560) at 3000 g, 5 min, at 4 oC. The separated serum
was stored at –80 oC (NUAIRE Ultra-Low Freezer Model
no: Nu-6420E) until biochemical analyzes.
2.3. Biochemical measurements
BDNF levels were measured using Human BDNF Elisa
Kit (Boster, California, USA. Cat No: EK0307 Lot No:
361144504). The sensitivity was <2 pg/mL, intraassay
and interassay CV were 4.2% and 7.5% respectively. NGF
levels were measured using Human NGF/NGF-β Elisa
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Kit (Boster, California, USA. Cat No: EK0469 Lot No:
1881116427). The sensitivity was <1 pg/mL, intraassay
and interassay CV were 7.2% and 8.1% respectively. NT-3
levels were measured using Human Neurotrophin-3 Elisa
Kit (Boster, California, USA. Cat No: EK0472 Lot No:
19110128427). The sensitivity was <2 pg/mL, intraassay
and interassay CV were 4.9% and 6.1% respectively.
GDNF levels were measured using Human GDNF Elisa
Kit (Boster, California, USA. Cat No: EK0362 Lot No:
851034427). The sensitivity was <4 pg/mL, intraassay
and interassay CV were 5.7% and 8.2% respectively.
VEGF levels were measured using Human VEGF Elisa
Kit (Boster, California, USA. Cat No: EK0539 Lot No:
2531133427). The sensitivity was < 1 pg/mL, intraassay
and interassay CV were 4.2% and 7.5% respectively. IGF-1
levels were measured using IGF-1-EASIA Kit (DIAsource,
Louvain-la-Neuve, Belgium, Katalog No: KAP1581, Lot
No: 151101). The detection limit was 7.8 ng/mL, intraassay
and interassay were CV 6.1% and 12.9% respectively. FGF2 levels were measured using Human (FGF2) ELISA Kit
(Sunred, Shanghai, China, Katalog No: 201-12-0056,
Lot No: 201505). The detection limit was 4.458 ng/
mL, intraassay and interassay CV were <10% and <12%
respectively. Nrn 1 levels were measured using Human
Neuritin (NRN1) ELISA Kit (CUSABIO, Wuhan, China,
Katalog No: CSB-EL016088HU, Lot No: K11162142). The
detection limit was 7.8 pg/mL, intraassay and interassay
CV were <8% and <10% respectively. Cortisol levels were
measured with chemiluminescence method using Roche
Diagnostic E170 autoanalyzer. The detection limit was 1.5
nmol/L, intraassay and interassay CV were 2.4% and 2.8%
respectively.
2.4. Statistical analysis
SPSS for Windows 15.0. was used for statistical analysis.
The normal distribution of the data was checked with
Kolmogorov-Smirnov normal distribution test. The
comparison of categorical data was analyzed with chisquare test while continuous parameters were compared
with independent samples ttest and Mann-Whitney U test.
To control the effect of potential confounding factors (age,
BMI and cortisol level) on statistical difference, analysis
of covariance (ANCOVA) was used. We conducted
correlation analyses for biochemical parametres
themselves. We also analyzed the correlation between
biochemical parametres and, clinical and demographical
features of the patients. Pearson and Spermann correlation
method were used. To control the effect of the confounding
factors on correlations, partial correlation analysis was
applied. ROC analysis was conducted in order to evaluate
diagnostic value of biochemical parametres for which there
were statistical differences among the groups. A value of P
< 0.05 was considered as significant. Results were given as
mean ± standart deviation.

3. Results
There was no statistical difference between the control
group and the bipolar manic episode patients with respect
to the age, sex and BMI (P > 0.05). There were differences
between the groups with respect to the socioeconomic
status (P < 0.05). Of all the patients, 3 (6.7%) patients had
suffered 1, and 4 (8.9%) patients had suffered 2 attacks
of hypomania. Two of the patients (4.4%) had had a
mixed attack while 17 patients (37.8%) had had only one
depression attack. Clinical and demographical features of
the subjects are presented in Table 1.
In the first statistical analysis disregarding the
confounding factors (age, BMI, cortisol), it was revealed
that there was no difference between the groups regarding
cortisol, BDNF, NGF and NT-3 levels (P = 0.154, P = 0.178,
P = 0.205 and P = 0.155 respectively). However, there were
statistical differences between the groups with regard to
GDNF, VEGF, IGF-1, FGF-2 and Nrn 1 levels (P values
were P = 0.001, P = 0.023, P = 0.000015, P = 0.013, P =
0.021 respectively). In the second statistical analysis, age,
BMI and cortisol were taken under control to eliminate
the effects of these parametres. The statistical analysis
showed that statistical difference persisted in GDNF, IGF1 and Nrn 1 levels (P = 0.003, P = 0.0001 and P = 0.025
respectively) while there were no statistical differences
in VEGF and FGF-2 levels (P = 0.149 and P = 0.078
respectively). All data are presented in Table 2.
When age, BMI and cortisol level were taken under
control in the correlation analysis, there was a statistically
significant correlation between only Nrn 1 and BDNF in
the control group (r = 0.383, P < 0.021). In the patient
group, there was no correlation neither among the
biochemical parametres themselves nor the clinical and
demographical features of the patients.
ROC analysis was performed on the biochemical
parametres in which the groups had statistical differences
and the area under the the curve was calculated as 0.737,
0.766 for GDNF and IGF-1, respectively. (Figures 1 and 2,
Table 3)
4. Discussion
The evidence about structural abnormalities of the brain
in bipolar disorder is increasing [36]. Neurotrophic
factors are among the most important factors underlying
these changes. Although the data collected on the role
of neurotrophines in the pathophysiology of bipolar
disorder has increased, they are conflicting and far from
being sufficient [12]. Moreoever, it is argued that these
neurotropic factors also change in other psychiatric
diseases such as major depression and schizophrenia,
which implies that the change in these factors may not be
unique to bipolar disorder [37,38]. In order to reveal this
point, we kept cortisol level, BMI and age under control
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Table 1. Clinical and demographical features of the subjects.
Control (n = 45)

Patient (n = 45)

P

34.91 ± 10.76

34.91 ± 10.76

1.00a

Male

23 (51.1)

23 (51.1)

Female

22 (48.9)

22 (48.9)

Low

3 (6.7

8 (17.78

Middle

41 (91.1)

30 (66.67)

2 (2.2)

7 (15.56)

21.95 ± 2.4

21.27 ± 2.12

Age, mean ± SD (years)
Sex, n (%)

1.00b

Socioeconomical status, n (%)

High
BMI (kg/m ), mean ± SD
2

YMRS, mean ± SD

40.11 ± 8.12

Number of episode, mean ± SD

5.22 ± 4.55

Number of manikepisode,mean ± SD

4.00 ± 3.66

0.014b
0.177b

First episode, n (%)
Mania

13 (28.9)

Depression

32 (71.1)

Age of onset, mean ± SD (years)

25.00 ± 8.78

Duration of disease, mean ± SD (years)

9.82 ± 6.86

Suicide attempt n (%)
Family history for
psychiatric disorder n (%)
Bipolar disorder

5 (11.1)

Schizophrenia

1 (2.2)

Depression

2 (4.4)

10 (22.2)
7 (15.6)

Medicines used, n (%)
Lithium carbonate

14 (31.1)

Valproic acid

30 (66.7)

Lamotrigine

1 (2.2)

Antipsychotics,n (%)

a

Non

1 (2.2)

First generation

2 (4.4)

Second generation

34 (75.6)

First + Second generation

8 (17.8)

Independent samples t-test, bChi-square test.

statistically in the groups and we found that GDNF and
Nrn 1 levels were significantly lower while IGF-1 levels
were significantly higher in bipolar manic episode patients
compared to the control group. On the other hand, there
were no differences among the groups with respect to
BDNF, NGF, NT-3, VEGF and FGF-2 levels.
BDNF is the most commonly studied neurotrophic
factor in bipolar disorder. There are studies in which BDNF
increased [39, 40], decreased [41] or remained unchanged
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[42]. However, the decrease in BDNF may particularly
be observed in long-term bipolar patients [43]. Two
postmortem studies also showed that BDNF decreased
in brain tissue [6, 44]. In order to minimize the effects of
confounding factors, we matched the patient group and
the control group with respect to age and sex. In addition,
patients with a body index of BMI >25 were excluded.
We found no difference in BDNF levels. Possibly, the
BDNF level could be normalized as a result of medication.
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Table 2. Biochemical parametres.
Control (n = 45)

Patient (n = 45)

P

U,t,F value

BDNF (pg/mL)

6551.00 ± 1912.69

7182.32 ± 1638.35

0.178

M-W U = 826

NGF(pg/mL)

36.29 ± 14.53

32.59 ± 12.20

0.205

t = 1.277

NT-3 (pg/mL)

89.59 ± 60.87

110.68 ± 70.35

0.155b

t = –1.437

GDNF (pg/mL)

2785.31 ± 1255.91

1733.47 ± 1201.19

0.003

F = 9.335

VEGF (pg/mL)

52.69 ± 24.12

62.25 ± 24.67

0.149c

IGF-1 (ng/mL)

190.68 ± 56.58

279.30 ± 139.54

0.0001

F = 15.930

FGF-2 (ng/mL)

837.68 ± 432.98

653.38 ± 404.78

0.078c

F = 3.176

Nrn 1 (pg/mL)

173.89 ± 114.38

121.19 ± 72.38

0.025

c

F = 5.281

Cortisol

14.43 ± 5.24

12.92 ± 4.64

b

0.154

t = 1.439

a
b

c

F = 2.125
c

BDNF: Brain-derived neurotrophic factor, NGF: Nerve growth factor, NT-3: Neurotrophin-3, GDNF:
Glial cell-line derived neurotrophic factor, VEGF: Vascular endothelial growth factor, IGF-1: Insulin-like
growth factor-1, FGF-2: Fibroblast growth factor, Nrn 1: neuritin 1.
a
Mann-Whitney U test, bIndependent samples t-test, cAnalysis of covariance (ANCOVA) controlling for
age, BMI and cortisol.

Figure 1. ROC curve for GDNF.

Although there are studies on this subject, it is not possible
to explain this result clearly because medication-free
patients were not examined sufficiently [41, 45]. Another
factor is the possiblity of reaching different results at
different episodes of bipolar disorders. Decisive decreases

may occur in the depressive episode of bipolar disorder
[46]. Similar to the results obtained for BDNF, we did not
observe any difference between the groups with regard to
NGF and NT-3 levels. Although Liu et al. reported that
NGF level increased in medication-free manic episode
patients [13], another study showed that it decreased
in the manic episode [7]. It is proposed that NT-3 level
increased in different episodes of bipolar disorder [5,
47]. The measurement methods used in these studies are
similar to ours. As for the NGF values, a study reported
that the standard deviation of NGF values was quite wide
while the other study showed that the standard deviation
was both quite wide and close to the detection limit as we
found in this study. This shows that the method used to
measure the NGF level may be an important limitation,
which requires the use of more precise methods. On the
other hand, the limited number of patients examined in
studies conducted to evaluate NT-3 level appears to be a
significant limitation. Although it was reported that NGF
and NT-3 levels of the peripheral tissue reflected those of
the brain [48], these molecules transmit to the blood at low
concentrations, which may explain the low levels of these
molecules in blood.
One of the significant findings of our study is the low
level of GDNF in bipolar disorder patients. The statistical
difference between the patients and the control group
persisted even when the confounding factors were taken
under control. There are studies in literature which found
low levels of GDNF in manic episode patients, as well [49,
50]. We conducted ROC analysis to show that GDNF level
might indicate the episode of the disorder and found that
area under the the curve was 0.737, which was an interesting
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Figure 2. ROC curve for IGF-1.

finding (Figure 1, Table 3). In the correlation analysis, we
did not find any correlation between the GDNF level and
the clinical features of the disorder, which was contrary
to the findings of some studies [45, 51]. However, serum
GDNF level may not reflect the level of GDNF in central
nervous system because it can hardly pass the blood-brain
barrier. It is known that GDNF production takes place in
peripheral tissues [10]. The study of the correlation between
the level of GDNF in brain and peripheral tissues requires
further attention. Another point is that medication, lithium
in particular may have an effect on GDNF levels. It was
reported that there was a negative correlation between
serum lithium levels and GDNF [40]. In our study, reduced
levels of GDNF may be due to lithium used by the patients.

There were statistical differences between the groups
with regard to VEGF, IGF-1 and FGF-2 when confounding
factors were not taken under control. However, when
the confounding factors were taken under control, the
difference between the groups persisted in the IGF-1 level
while there were no differences between the groups for
VEGF and FGF-2 levels. There are 2 studies reporting that
VEGF level increased in manic [16] and depressive [52]
episodes of bipolar disorder. The difference between these
studies and ours may result from the different confounding
factors taken under control. While Lee and Kim [16]
reported that statistical difference persisted when BMI was
taken under control as the confounding factor, Shibata et
al. [52], in another study, did not take BMI and cortisol
level under control as confounding factors. Another
factor contributing to the difference in the results is that
the drugs used may affect the VEGF level. It was reported
that lithium reduced the VEGF level [53]. We divided the
patient group into 2 subgroups as those who used lithium
and who used valproic acid and, found that there was no
difference between them with regard to VEGF levels (P
= 0.539). Although it was reported in another study [13]
that FGF-2 level increased in the manic episode, there was
no difference between the groups in our study. The most
important difference between the study conducted by Liu
et al. [13] and our study is that they did not control the
confounding factors. In a postmortem study, it was found
that FGF-2 and FGFR1 levels did not change in the brain
in bipolar disorder patients [21]. However, further studies
are required to reveal the relationship between FGF-2
and bipolar disorder. As for IGF-1 values, Palomino et
al. [54] found the same level of IGF-1 in bipolar disorder
patients and control group and, Kim et al. [19] found a
high level of IGF-1, which is similar to our study. It was
reported that the level of IGF-1 produced in the peripheral
tissue affected the cognitive functions of the brain [17].
The effect of IGF-1 on the brain is principally achieved via
insuline-like growth factor binding protein 2 (IGFBP2)
and it was found that the level of this protein was low in
the prefrontal cortex of bipolar patients [18]. In addition,
the polymorphism occuring in IGF-1 gene may have an

Table 3. ROC analysis values.
Test result
variable(s)

Area

Std. error
(a)

Asymptotic sig.
(b)

Asymptotic 95% confidence interval
Upper bound

Lower bound

GDNF

0.737

0.059

0.001

0.621

0.854

IGF-1

0.766

0.051

0.000

0.666

0.867

Nrn 1

0.626

0.067

0.069

0.495

0.758

a: Under the nonparametric assumption, b: Null hypothesis: true area = 0.5.
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important role in the emergence of bipolar disorder [55].
IGF-1 level, which loses its ability to affect the central
nervous system as a result of genetical polymorphism
and decrease in IGFBP2 level, may increase in order to
compensate this. However, the drugs used, particularly
lithium, may increase the IGF-1 level [56]. In the light of
this information, we found that IGF-1 levels of the patients
who used lithium were not different from those of the
patients who used valproic acid (P = 0.604). In addition,
the ROC analysis we conducted suggested that high level
of IGF-1 may be used as a status marker for bipolarmanic
episode patients (Figure 2)
We did not find any literature data examining the
level of serum Nrn 1. However, in a recent study, it was
proposed that single nucleotid polymorphism of Nrn 1
gene in schizophrenia and bipolar patients was a risk factor
for the emergence of these diseases [57]. It was reported
that chronic stress reduced the production of neuritin
in hippocampus and that the administration of neuritin
increased the production of hippocampaldendiritic
complex [25]. Nrn 1 and NGF have synergistic effects [58]
and elevated level of it after neuronal degradation may
show its role on regeneration process [59]. In our study, we
found that Nrn 1 level was low in bipolar manic episode
patients. In addition, there was a correlation between Nrn
1 and BDNF levels in the control group but there was no
correlation between these values in the patient group. The
low level of Nrn 1 may lead to a weakness in the repair of

damaged neurons or may reflect the neurodevelopmental
aspect of bipolar disorder. Hovewer this hypothesis needs
to be supported with new research.
In this study, there are several limitations. One of these
was that biochemical parameters are measured in serum
and how the serum neurotrophin values reflect the state of
the central nervous system is not clear. Second limitation
was that the patient group was not drug naive or drug-free
and the therapeutic drugs may affect the neurotrophins
levels. Third limitation was that we investigated the patients
only during the manic episode. Euthymic and depressive
episodes could not be evaluated. Fourth limitation was that
the study had a relatively small number of participants.
In conclusion, we found low GDNF and Nrn 1 levels
and, high IGF-1 level in bipolar patients with mania.
Hovewer, GDNF and IGF-1 may be used as state markers
and these findings will be helpful for the development of
new treatment strategies which include neurotrophins for
bipolar disorder in the future. But these findings must be
supported by new reseach involving euthymic episode.
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